Piper Sandler analyst Jessica Tassan downgraded Phreesia to Neutral from Overweight with a price target of $12, down from $23. Phreesia is cutting costs to find profitability, but without a clear path back to durable organic revenue growth, notes the analyst, who is \"wary of this strategy\" in healthcare IT.
